HOME >> MEDICINE >> NEWS
NIAID researchers show how promising TB drug works

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined how a promising drug candidate attacks the bacterium that causes tuberculosis (TB). Published online this week in Proceedings of the National Academy of Sciences, the finding may help scientists optimize the drug candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb).

"PA-824, now in early stage clinical trials, holds promise for shortening the TB treatment regimen, which is currently cumbersome and lengthy," says NIAID Director Anthony S. Fauci, M.D. "This new finding will allow a streamlined approach for making improved versions of the drug."

"Previously, we were flying blind in trying to optimize PA-824 in a rational way because we didn't know which M. tb protein was the target of PA-824's action," says NIAID scientist Clifton Barry, III, Ph.D., who headed the research team.

In preclinical testing, PA-824 showed evidence of being effective against both actively dividing and slow-growing M. tb, giving rise to optimism that the compound may be useful in treating both active and latent TB. (For information about the first clinical trial of PA-824, see June 14, 2005, NIAID press release: http://www3.niaid.nih.gov/news/newsreleases/2005/tb_pa_824.htm.)

PA-824 must be chemically activated in the bacterium before it exerts its anti-tubercular effect, notes Dr. Barry. Earlier research had sketched out the first few steps in this process, but Dr. Barry and his colleagues wanted to pinpoint the precise protein that binds PA-824 and transforms it into a lethal molecule for TB.

The scientists approached the problem indirectly by searching for M. tb mutants that resisted the killing power of PA-824. The team confirmed previous research suggesting that resistance usually occurs when M. tb lacks components
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Dec-2005


Page: 1 2 3

Related medicine news :

1. NIAID releases MDR/XDR Tuberculosis research agenda
2. NIAID DNA vaccine for H5N1 avian influenza enters human trial
3. NIAID media availability: Examining genetic variability of malaria parasite offers insight
4. NIAID awards $4 million to develop anti-radiation treatments
5. Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
6. NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
7. NIAID study finds higher dose of flu vaccine improves immune response in the elderly
8. NIAID media availability: New study describes key protein from highly pathogenic H5N1 avian flu virus and how it might mutate
9. NIAID media availability: Understanding influenza infection
10. NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats
11. NIAID launches first Phase II trial of a global HIV/AIDS vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/22/2018)... ... 20, 2018 , ... A July 12 article in Glamour offers examples of six ... who obtained a weight loss surgery after she was moved to take more control of ... and a half years, she lost close to 90 pounds following her sleeve gastrectomy. “Bariatric ...
(Date:7/22/2018)... (PRWEB) , ... July 20, 2018 , ... Dr. Joseph ... groundbreaking medical devices for cardiology patients after retiring and resigning as a part-time adjunct ... , “I have enjoyed serving on the Johns Hopkins faculty for many ...
(Date:7/22/2018)... ... ... Novant Health is pleased to announce that Chad Setliff will be the new ... Setliff, who begins in the new role on Aug. 12, most recently served as ... Health Clemmons Medical Center. Before that, he was president and COO of Novant Health ...
(Date:7/22/2018)... ANGELES (PRWEB) , ... July 20, 2018 , ... Cosmetic Town, a Los Angeles based ... easier for patients. The website is starting the publication of a series of lists that ... , According to the senior editor of Cosmetic Town , “San Diego is often ...
(Date:7/22/2018)... ... July 21, 2018 , ... "Business Matrix" is a ... Now, in an upcoming episode, the program will focus on sports injury prevention. , ... healthy lifestyle, as well as to have fun or compete professionally. Unfortunately, all sports ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
Breaking Medicine Technology:
Cached News: